Zelira Therapeutics Dividend

Dividend criteria checks 0/6

Zelira Therapeutics no tiene antecedentes de pago de dividendos.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-AU$3.21
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

Stability and Growth of Payments

Fetching dividends data

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ZLD han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ZLD han aumentado.

Dividend Yield vs Market

Zelira Therapeutics Dividend Yield vs Market

How does ZLD dividend yield compare to the market?
Segment	Dividend Yield
Company (ZLD)	n/a
Market Bottom 25% (AU)	2.6%
Market Top 25% (AU)	6.1%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (ZLD)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ZLD en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ZLD en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Earnings Payout to Shareholders

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de ZLD para determinar si sus dividendos están cubiertos por los beneficios.

Cash Payout to Shareholders

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ZLD no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Zelira Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

New major risk - Negative shareholders equity

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Full year 2023 earnings released: AU$0.55 loss per share (vs AU$1.49 loss in FY 2022)

Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released

New minor risk - Financial data availability

New major risk - Market cap size

Zelira Therapeutics Limited Announces Board Changes

Zelira Therapeutics Limited announced that it expects to receive $22 million in funding

First half 2023 earnings released: AU$0.38 loss per share (vs AU$0.81 loss in 1H 2022)

Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director

No independent directors

Zelira Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets

Zelira Therapeutics Limited Completes Two-Thirds of Enrolment for Diabetic Nerve Pain Drug Trial

Full year 2022 earnings released: AU$1.54 loss per share (vs AU$1.29 loss in FY 2021)

Zelira's Zenivol™, the First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Zelira Therapeutics Ltd Publishes White Paper Detailing the Analysis of Longitudinal, Real-World Data Generated from Patients Using ZENIVOL

Zelira Therapeutics Ltd Announces Resignation of Harry Karelis as Non-Executive Vice Chairman

Zelira Therapeutics Limited Successfully Launches ITURA with CVSCM

No independent directors

Zelira Therapeutics Limited Appoints Timothy Slate as Director

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Zelira Therapeutics Limited Launches RAF FIVE Acne Treatment Products

Zelira Therapeutics Ltd Obtains IRB Approval for US Observational Clinical Pain Trial

Zelira Therapeutics Ltd. Announces Clinical Trial Results of Zelira's Zenivol Published in the Prestigiouspeer-Reviewed Journal Sleep

Zelira Therapeutics Limited Researchers Develops New Technology to Improves Delivery of CBD into Brain

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

MD & Director has left the company

Zelira Therapeutics Limited Announces Executive Changes

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Zelira Therapeutics Ltd Announces to Enter into A Binding Licensing Agreement with Alternative Solutions LLC

ZLD Partners with SprinJene to Launch CBD Toothpaste in US

Zelira Therapeutics Limited announced that it expects to receive AUD 1.999998 million in funding from Thorney Investment Group Australia Pty. Ltd.

Zelira Therapeutics Ltd. Announces Zenivol Launches in Australia After TGA Approves Release

Zelira Therapeutics Limited announced that it has received AUD 8.749378 million in funding

Zelira Therapeutics Limited announced that it expects to receive AUD 8.749378 million in funding

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies